A carregar...
Future Directions in Myelodysplastic Syndrome: Newer Agents and the Role of Combination Approaches
Myelodysplastic syndrome (MDS) is not a single disease, but a collection of hematopoietic disorders that require newer strategies. Currently, azacitidine, decitabine, and lenalidomide are approved by the US Food and Drug Administration for the treatment of MDS. A recent study demonstrated an improve...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2727156/ https://ncbi.nlm.nih.gov/pubmed/18813208 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|